Step-by-Step Guide to Preparing Clinical Trial Data for Public Repositories

Introduction: Why Proper Data Preparation Matters

As global regulations and journal policies increasingly demand open access to clinical trial data, researchers and sponsors must prepare datasets in formats suitable for public repositories. Improper or incomplete preparation can lead to regulatory delays, data misuse, or breaches of participant confidentiality. Therefore, data preparation is not just a technical step — it’s a regulatory, ethical, and scientific responsibility.

Preparing data for public sharing involves several critical activities: de-identification, metadata annotation, format conversion, documentation, and repository selection. This guide provides a detailed, compliant approach tailored to global expectations, including FDA, EMA, WHO, and ICMJE requirements.

Step 1: Define the Scope of Data for Sharing

The first step is identifying which components of the clinical trial dataset will be shared. Typical elements include:

• De-identified patient-level datasets (e.g., demographic, baseline, outcomes)
• Study protocol and statistical analysis plan (SAP)
• Case Report Forms (CRFs) or annotated CRFs
• Clinical Study Report (CSR)
• Data dictionaries and codebooks
• Data sharing plan and user guides

Ensure that shared data aligns with what was described in the trial’s data sharing statement and informed consent documents.

Step 2: Anonymize or De-Identify the Dataset

To comply with privacy regulations like GDPR and HIPAA, data must be fully anonymized or de-identified. Techniques include:

• Removing direct identifiers (e.g., name, phone number, social security number)
• Generalizing or binning date-of-birth, geographic location, or visit dates
• Replacing identifiers with subject IDs
• Using controlled randomization for sensitive categories (e.g., rare diseases)

De-identification must be irreversible. It’s best practice to document the method and date of anonymization in a separate file.

Sample De-Identification Table

Step 3: Format the Data for Compatibility

Public repositories often require datasets in specific formats. Common formats include:

• CSV or TSV for tabular datasets
• XML or JSON for structured submissions (e.g., to CTRI)
• SAS XPORT or CDISC-compliant SDTM/ADaM files for FDA submissions

All files should be checked for readability, encoding compatibility (e.g., UTF-8), and must exclude macros or embedded formulas.

Step 4: Create a Comprehensive Data Dictionary

A data dictionary explains every variable in the dataset, including its format, possible values, units, and logic. It ensures data usability for secondary researchers. A basic structure might include:

Step 5: Prepare Metadata and Documentation

Metadata is machine-readable information that describes the dataset. It includes trial identifiers, data collection dates, responsible parties, and sharing conditions. Recommended metadata standards include:

• Dublin Core: for basic bibliographic metadata
• DataCite: for DOI-based repositories
• Clinical Data Interchange Standards Consortium (CDISC): for FDA/EMA submissions

Also include README files explaining file structure, naming conventions, and how to interpret the dataset.

Step 6: Review Legal, Ethical, and Policy Considerations

Before uploading, review institutional, national, and funder requirements. Confirm that:

• Ethics Committee/IRB approval covers data sharing
• Participant informed consent permits secondary use
• Any data transfer agreements (DTAs) are executed if required
• Embargoes or publication rights are respected

Include a plain language data sharing statement in the documentation pack.

Step 7: Choose and Upload to the Appropriate Repository

Repository selection depends on the trial type, sponsor policy, and access model:

• Open Repositories: Dryad, Figshare, Zenodo
• Controlled Repositories: Vivli, YODA Project, EMA Data Portal
• Regulatory Registries: ClinicalTrials.gov, EU CTR, ISRCTN

Ensure that files are uploaded with the correct metadata, license, and access controls. For example, CSVs should be accompanied by data dictionaries and README files.

Step 8: Assign Persistent Identifiers and License

Assigning a DOI (Digital Object Identifier) ensures that your dataset can be cited and tracked. Choose an appropriate license such as:

• CC BY 4.0: Permits sharing and reuse with attribution
• CC0: Public domain dedication
• Restricted use: With justified embargoes

Use repositories that support DOI minting and license tagging.

Step 9: Validate Data Before Submission

Perform internal validation checks to ensure data completeness, readability, and compliance:

• File naming matches SOP convention
• No missing columns or variables
• Consistency with the Clinical Study Report
• Compatibility with statistical software (e.g., R, SAS)

Include a final checklist in the submission folder for review before public release.

Conclusion: Building a Culture of Responsible Data Sharing

Well-prepared data sets enable meaningful secondary research, reinforce transparency, and meet growing global expectations. By integrating good data stewardship practices into clinical trial workflows, sponsors and investigators contribute to reproducibility, ethical research use, and patient trust. Following the steps above ensures data is not only shared — but shared responsibly and usefully for global health advancement.

What a Biostatistician Does Every Day in Clinical Trials

1. Understanding the Role of a Biostatistician in Clinical Trials

Biostatisticians play a pivotal role in the success of clinical trials. Their job goes far beyond analyzing data — they help design the study, define the endpoints, manage randomization, write the Statistical Analysis Plan (SAP), and oversee statistical programming and validation. A clinical biostatistician ensures that the data generated from trials are scientifically sound, statistically valid, and compliant with regulatory expectations like those outlined in ICH E9.

Whether working in a pharma company, Contract Research Organization (CRO), or as part of an academic research institute, their work touches nearly every phase of the clinical lifecycle — from protocol development to submission dossiers.

2. Pre-Trial Responsibilities: Protocol Review and SAP Drafting

Each day may begin with reviewing the study protocol. The biostatistician ensures the study design aligns with the intended endpoints. They focus on:

• ✅ Reviewing inclusion/exclusion criteria to ensure measurable outcomes
• ✅ Evaluating the proposed sample size calculation based on power analysis
• ✅ Drafting or reviewing the Statistical Analysis Plan (SAP)

The SAP is a critical document that lays out how statistical analysis will be performed. It defines primary and secondary endpoints, analysis populations (e.g., ITT, PP), missing data handling, and statistical methods like ANCOVA, logistic regression, or survival analysis.

According to PharmaGMP.in, SAPs should be finalized before database lock and aligned with the protocol and CRF design.

3. Randomization Schedules and Blinding

Biostatisticians are also responsible for generating and maintaining randomization schedules. These schedules define how subjects are assigned to treatment arms, using methods such as:

• ✅ Simple randomization
• ✅ Block randomization
• ✅ Stratified randomization

In blinded studies, the biostatistician must coordinate with unblinded teams to maintain trial integrity. Tools such as SAS macros or validated randomization software are often used to generate these lists securely, and output is shared with the IWRS vendor or the designated unblinded statistician.

4. Data Review and Ongoing Monitoring Support

During the conduct phase, the biostatistician regularly reviews data listings, tables, and summaries generated by the programming team. They also support:

• ✅ Data Monitoring Committee (DMC) meetings
• ✅ Interim analyses (IA)
• ✅ Safety signal detection

They may work with medical monitors and data managers to review protocol deviations or outliers. If a study has an interim analysis, the biostatistician ensures the statistical code and simulations are finalized and that the IA results do not compromise the blinding or introduce bias.

5. Statistical Programming and Analysis Execution

Biostatisticians either perform or closely supervise statistical programming. Commonly used tools include SAS, R, and occasionally Python. Typical tasks include:

• ✅ Developing statistical analysis datasets (ADaM)
• ✅ Executing tables, listings, and figures (TLFs)
• ✅ Validating code written by statistical programmers

For example, a biostatistician may run a repeated-measures ANCOVA for a chronic pain trial where scores are recorded weekly. Using SAS PROC MIXED or PROC GLM, they execute the model and interpret estimates, confidence intervals, and interaction terms.

All output must undergo rigorous QC before being included in the Clinical Study Report (CSR).

6. Regulatory Submission Preparation and Review

As the trial concludes, the biostatistician plays a central role in preparing regulatory submissions. This includes:

• ✅ Providing statistical inputs to the CSR
• ✅ Preparing integrated summaries for FDA or EMA submissions
• ✅ Reviewing and responding to Health Authority queries

In one example, during an NDA submission for a diabetes drug, the biostatistician prepared an Integrated Summary of Efficacy (ISE) and an Integrated Summary of Safety (ISS) in CDISC format. These were mapped to FDA requirements and submitted through eCTD format, following FDA Study Data Standards.

7. Cross-Functional Collaboration and Communication

A significant portion of a biostatistician’s day involves communicating results and decisions to various stakeholders. This includes:

• ✅ Presenting to clinical teams and medical directors
• ✅ Collaborating with programmers and data managers
• ✅ Participating in protocol, SAP, and CSR review meetings

Effective communication ensures that the trial’s objectives are met and that interpretations are statistically sound and clinically meaningful. Biostatisticians are often the bridge between raw numbers and actionable conclusions.

8. Continuous Learning and Process Improvement

Given the evolving regulatory landscape and statistical innovations, biostatisticians must keep themselves updated. Their ongoing activities may include:

• ✅ Attending workshops on Bayesian methods or adaptive designs
• ✅ Learning new tools like R Shiny for interactive visualizations
• ✅ Participating in internal process improvement teams

Continuous development ensures compliance with the latest ICH and GCP requirements while improving trial efficiency.

9. Conclusion

The daily work of a clinical trial biostatistician is complex, multi-faceted, and mission-critical. From designing protocols to delivering regulatory-ready data, biostatisticians ensure the scientific credibility of every result. A well-trained statistician is both a guardian of data integrity and a key strategist in trial success.

References:

• PharmaValidation: GxP Templates for Biostatistics and Programming
• ICH E9 Statistical Principles
• FDA Drug Development Tools

How CDASH Guidelines Define CRF Standards in Clinical Trials

Standardization in clinical data collection is vital for trial efficiency, data quality, and regulatory compliance. The Clinical Data Acquisition Standards Harmonization (CDASH) initiative provides structured guidelines for designing Case Report Forms (CRFs) that align with broader CDISC data standards. This tutorial explores the principles of CDASH, how it supports CRF standardization, and the benefits it brings to sponsors, sites, and regulators.

What Is CDASH?

CDASH stands for Clinical Data Acquisition Standards Harmonization. Developed by CDISC (Clinical Data Interchange Standards Consortium), CDASH defines standardized data collection fields, formats, and terminologies to be used in CRFs across clinical studies. It ensures that data captured at the source can seamlessly map to SDTM (Study Data Tabulation Model) datasets required for regulatory submission.

CDASH is widely supported by global regulatory agencies, including the USFDA, EMA, and others.

Why CRF Standards Matter:

Standardized CRFs help reduce inconsistencies, facilitate automation, and improve data traceability. They also:

• Enhance study startup speed
• Improve cross-study comparisons
• Reduce CRF errors and queries
• Support downstream SDTM mapping
• Align with global regulatory submission formats

Using CDASH improves consistency across multiple trials and reduces duplication in GMP documentation and data management efforts.

Key Components of CDASH Guidelines:

CDASH provides a library of standard domains and variable names for commonly collected data. These include:

• Demographics (DM)
• Adverse Events (AE)
• Medical History (MH)
• Concomitant Medications (CM)
• Vital Signs (VS)
• Informed Consent (IC)

Each domain contains:

• Variable Name: e.g., AEDECOD (Adverse Event Term)
• CDASH Label: Human-readable field label for CRFs
• Data Type: Text, date, numeric
• Controlled Terminology: e.g., MedDRA, WHO-DD

How CDASH Supports CRF Design:

CRF designers use CDASH to ensure each data element:

• Has a defined name and structure
• Maps directly to SDTM domains
• Uses standard labels and terminologies
• Aligns with the trial protocol and statistical analysis plan

By using CDASH domains, CRFs become more regulatory-compliant and interoperable across systems.

Best Practices for Implementing CDASH in CRF Design

1. Start with a CDASH-Aligned CRF Template

Leverage standard templates from CDISC or EDC vendors that reflect CDASH labels and structure. These can be adapted to specific protocols while maintaining consistency.

2. Use Controlled Terminology

Ensure fields use standard coding dictionaries such as MedDRA (for adverse events) or WHO-DD (for medications). This ensures accurate mapping and minimizes ambiguity.

3. Annotate CRFs with Metadata

Include annotations for SDTM variable names next to CRF fields. This facilitates automated mapping and simplifies data review by regulatory authorities.

4. Integrate into SOPs and Training

Embed CDASH implementation into organizational SOP compliance pharma and train data managers and CRF designers accordingly.

5. Conduct Peer Review and Testing

Review CRFs for adherence to CDASH standards before deployment. Test them in the EDC environment to ensure correct logic, structure, and user experience.

Benefits of CDASH-Compliant CRFs:

• Faster trial setup with reusable components
• Reduced CRF completion errors
• Simplified integration with EDC and data warehouses
• Improved regulatory submission quality
• Consistency across global trials

In long-term studies, CDASH-aligned CRFs facilitate consistent tracking of Stability Studies and pharmacovigilance data across timepoints.

Case Study: Using CDASH in a Multinational Trial

A Phase III cardiology study across 8 countries adopted CDASH-compliant CRFs. Benefits realized:

• 30% faster form design and approval process
• 75% reduction in terminology queries
• Easy mapping to SDTM for regulatory submission

This helped streamline the submission package to the EMA and reduced rework during validation checks.

Challenges and How to Overcome Them:

While CDASH provides structure, challenges include:

• Resistance to change from custom CRF practices
• Complex protocols that require non-standard data
• Learning curve for new users

Solutions:

• Provide training and documentation aligned with pharmaceutical validation standards
• Use hybrid CRFs where CDASH forms the core, and custom modules address unique protocol needs
• Ensure regulatory review and endorsement of deviations

Conclusion: CDASH is the Backbone of Standardized CRF Design

CDASH guidelines play a pivotal role in standardizing CRF design, promoting consistency, accuracy, and compliance in clinical trials. By embedding CDASH principles into CRF development, organizations can reduce errors, streamline submissions, and enhance data interoperability. Whether you’re designing a new CRF or optimizing existing forms, CDASH provides the foundation for modern, effective, and regulatory-ready data collection.

Helpful Internal Links:

• GMP training
• pharma regulatory requirements